Former NFL star Greg Buttle partners with electroCore for wellness device

ROCKAWAY, N.J. - Former New York Jets linebacker Greg Buttle has partnered with electroCore, Inc. (NASDAQ:ECOR) to promote the company’s Truvaga Plus device, according to a press release issued Thursday. The micro-cap medical device company, currently valued at approximately $39 million, has shown strong revenue growth of 30% over the last twelve months, according to InvestingPro data.

The handheld vagus nerve stimulation device is designed to promote relaxation, mental clarity and improved sleep quality through brief two-minute sessions.

"As an NFL linebacker, I had to be sharp, fast, and ready to hit every play. But you can’t bring that energy if you’re dragging from a bad night’s sleep," Buttle said in the statement. "This device has been a game-changer for me, helping me get the restorative sleep I need."

Truvaga Plus uses non-invasive stimulation of the vagus nerve to help shift the body from a stress response to a more balanced state. The partnership will include radio spots and digital campaigns highlighting the device’s wellness applications.

Kelly Benning, Senior Vice President of Truvaga at electroCore, said Buttle’s "leadership, credibility, and commitment to wellness" made him an ideal partner for the company.

The device is manufactured in the United States and draws on the company’s research in bioelectronic medicine. ElectroCore notes that Truvaga Plus is intended for general wellness purposes only and is not meant to diagnose or treat medical conditions.

The company also markets prescription neuromodulation products for chronic pain under its gammaCore and Quell brands. The stock has experienced significant volatility, falling more than 65% over the past six months, though InvestingPro’s Fair Value analysis suggests the shares may be undervalued at current levels.

In other recent news, electroCore Inc. reported a 20% year-over-year increase in revenue for the second quarter of 2025, reaching $7.4 million. Despite this growth, the company posted a net loss of $3.7 million, translating to a loss of $0.44 per share. The company projects a cash balance of approximately $10.5 million by the end of 2025, reflecting an optimistic financial outlook. Additionally, electroCore has made notable changes to its leadership team. Elena Bonfiglioli, a healthcare executive from Microsoft, joined the board of directors, replacing Peter Cuneo. In another leadership update, Kelly Benning was appointed as Senior Vice President of the Truvaga wellness division. Benning brings extensive experience in digital health and AI-enabled technologies to the company. These recent developments reflect electroCore’s ongoing strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.